Idarubicinol myelotoxicity: A comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin

C. Corsini, M. Ghielmini, P. Mancuso, F. Tealdo, M. Paolucci, M. Zucchetti, P. F. Ferrucci, E. Cocorocchio, M. Mezzetti, A. Mori, M. Riggi, M. D'Incalci, G. Martinelli

Research output: Contribution to journalArticle

Abstract

We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose-response curves. We treated 16 patients with poor prognosis lymphoma in a phase I-II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors. Colony inhibition was correlated with pharmacokinetic data and with the time of patients' engraftment. Plasma samples obtained before idarubicin treatment demonstrated a colony-stimulating effect, increasing the cloning efficiency by 72%. The inhibitory activity on colony forming unit granulocyte-macrophage (CFU-GM) of patients' plasma collected on the day of transplantation was lower than expected from dose-response curves (21% measured vs 70% expected). The time to patients' WBC and PLT recovery correlated with the amount of CD34+ cells reinfused and, to a lesser extent, with the colony-inhibiting effect of patients' plasma. The correlation between idarubicinol concentration and CFU-GM inhibition was not significant. These data suggest that plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells. (C) 2000 Cancer Research Campaign.

Original languageEnglish
Pages (from-to)524-528
Number of pages5
JournalBritish Journal of Cancer
Volume82
Issue number3
Publication statusPublished - 2000

Fingerprint

Idarubicin
Granulocyte-Macrophage Progenitor Cells
Transplantation
Melphalan
Anthracyclines
Fetal Blood
In Vitro Techniques
idarubicinol
Organism Cloning
Lymphoma
Stem Cells
Pharmacokinetics
Pharmaceutical Preparations

Keywords

  • CFU-GM growth inhibition
  • Haematotoxicity
  • High-dose chemotherapy
  • Idarubicin
  • Idarubicinol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Idarubicinol myelotoxicity : A comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. / Corsini, C.; Ghielmini, M.; Mancuso, P.; Tealdo, F.; Paolucci, M.; Zucchetti, M.; Ferrucci, P. F.; Cocorocchio, E.; Mezzetti, M.; Mori, A.; Riggi, M.; D'Incalci, M.; Martinelli, G.

In: British Journal of Cancer, Vol. 82, No. 3, 2000, p. 524-528.

Research output: Contribution to journalArticle

Corsini, C. ; Ghielmini, M. ; Mancuso, P. ; Tealdo, F. ; Paolucci, M. ; Zucchetti, M. ; Ferrucci, P. F. ; Cocorocchio, E. ; Mezzetti, M. ; Mori, A. ; Riggi, M. ; D'Incalci, M. ; Martinelli, G. / Idarubicinol myelotoxicity : A comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. In: British Journal of Cancer. 2000 ; Vol. 82, No. 3. pp. 524-528.
@article{d9d5ef8f88124d568436fd63d4ab19b2,
title = "Idarubicinol myelotoxicity: A comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin",
abstract = "We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose-response curves. We treated 16 patients with poor prognosis lymphoma in a phase I-II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors. Colony inhibition was correlated with pharmacokinetic data and with the time of patients' engraftment. Plasma samples obtained before idarubicin treatment demonstrated a colony-stimulating effect, increasing the cloning efficiency by 72{\%}. The inhibitory activity on colony forming unit granulocyte-macrophage (CFU-GM) of patients' plasma collected on the day of transplantation was lower than expected from dose-response curves (21{\%} measured vs 70{\%} expected). The time to patients' WBC and PLT recovery correlated with the amount of CD34+ cells reinfused and, to a lesser extent, with the colony-inhibiting effect of patients' plasma. The correlation between idarubicinol concentration and CFU-GM inhibition was not significant. These data suggest that plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells. (C) 2000 Cancer Research Campaign.",
keywords = "CFU-GM growth inhibition, Haematotoxicity, High-dose chemotherapy, Idarubicin, Idarubicinol",
author = "C. Corsini and M. Ghielmini and P. Mancuso and F. Tealdo and M. Paolucci and M. Zucchetti and Ferrucci, {P. F.} and E. Cocorocchio and M. Mezzetti and A. Mori and M. Riggi and M. D'Incalci and G. Martinelli",
year = "2000",
language = "English",
volume = "82",
pages = "524--528",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Idarubicinol myelotoxicity

T2 - A comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin

AU - Corsini, C.

AU - Ghielmini, M.

AU - Mancuso, P.

AU - Tealdo, F.

AU - Paolucci, M.

AU - Zucchetti, M.

AU - Ferrucci, P. F.

AU - Cocorocchio, E.

AU - Mezzetti, M.

AU - Mori, A.

AU - Riggi, M.

AU - D'Incalci, M.

AU - Martinelli, G.

PY - 2000

Y1 - 2000

N2 - We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose-response curves. We treated 16 patients with poor prognosis lymphoma in a phase I-II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors. Colony inhibition was correlated with pharmacokinetic data and with the time of patients' engraftment. Plasma samples obtained before idarubicin treatment demonstrated a colony-stimulating effect, increasing the cloning efficiency by 72%. The inhibitory activity on colony forming unit granulocyte-macrophage (CFU-GM) of patients' plasma collected on the day of transplantation was lower than expected from dose-response curves (21% measured vs 70% expected). The time to patients' WBC and PLT recovery correlated with the amount of CD34+ cells reinfused and, to a lesser extent, with the colony-inhibiting effect of patients' plasma. The correlation between idarubicinol concentration and CFU-GM inhibition was not significant. These data suggest that plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells. (C) 2000 Cancer Research Campaign.

AB - We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose-response curves. We treated 16 patients with poor prognosis lymphoma in a phase I-II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors. Colony inhibition was correlated with pharmacokinetic data and with the time of patients' engraftment. Plasma samples obtained before idarubicin treatment demonstrated a colony-stimulating effect, increasing the cloning efficiency by 72%. The inhibitory activity on colony forming unit granulocyte-macrophage (CFU-GM) of patients' plasma collected on the day of transplantation was lower than expected from dose-response curves (21% measured vs 70% expected). The time to patients' WBC and PLT recovery correlated with the amount of CD34+ cells reinfused and, to a lesser extent, with the colony-inhibiting effect of patients' plasma. The correlation between idarubicinol concentration and CFU-GM inhibition was not significant. These data suggest that plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells. (C) 2000 Cancer Research Campaign.

KW - CFU-GM growth inhibition

KW - Haematotoxicity

KW - High-dose chemotherapy

KW - Idarubicin

KW - Idarubicinol

UR - http://www.scopus.com/inward/record.url?scp=0033967369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033967369&partnerID=8YFLogxK

M3 - Article

C2 - 10682659

AN - SCOPUS:0033967369

VL - 82

SP - 524

EP - 528

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -